| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
AstraZeneca's Farxiga wins US approval to treat chronic kidney disease
StockMarketWire.com
|
Pharmaceutical giant AstraZeneca said Farxiga had been approved in the US to treat chronic kidney disease in patients at risk of progression with and without type-2 diabetes.
The approval by the Food and Drug Administration was based on positive results from the DAPA-CKD phase III trial.
The decision followed the priority review designation granted by the FDA earlier this year, the company said.
Story provided by StockMarketWire.com
|
|
|
|
|
|
